Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
 
Taj Logo
 
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
 

Metherlin Taj Products

 
HOME >> PRODUCTS >> metherlin [Preventing & Managing Uterine Hemorrhage]
Taj  ALL Products View Products According to Category


 

Preventing & Managing Uterine Hemorrhage

INDICATIONS
METHERLIN® (METHYLERGONOVINE MALEATE) IS INDICATED FOR ROUTINE MANAGEMENT OF UTERINE ATONY, HEMORRHAGE AND SUBINVOLUTION OF THE UTERUS FOLLOWING DELIVERY OF PLACENTA AND FOR CONTROL OF UTERINE HEMORRHAGE IN THE SECOND STAGE OF LABOR FOLLOWING DELIVERY OF THE ANTERIOR SHOULDER.

IMPORTANT SAFETY INFORMATION
Metherlin Tablets are contraindicated for patients with the following conditions: hypertension, toxemia, pregnancy, and hypersensitivity.
WARNINGS
General: This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Metherlin (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided. Caution should be exercised in presence of impaired hepatic or renal function.
Breast-feeding: Mothers should not breast-feed during treatment with Metherlin. Milk secreted during this period should be discarded. Metherlin may produce adverse effects in the breast-feeding infant. Metherlin may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of Metherlin before initiating or resuming breast feeding.
Coronary artery disease: Patients with coronary artery disease or risk factors for coronary artery disease (e.g., smoking, obesity, diabetes, high cholesterol) may be more susceptible to developing myocardial ischemia and infarction associated with methylergonovine-induced vasospasm.
Medication errors: Inadvertent administration of Metherlin to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as respiratory depression, convulsions, cyanosis and oliguria have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required. Metherlin has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, Metherlin injection should be stored separately from medications intended for neonatal administration.
PRECAUTIONS
General: Caution should be exercised in the presence of sepsis, obliterative vascular disease. Also use with caution during the second stage of labor. The necessity for manual removal of a retained placenta should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.
Drug Interactions: There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Caution should be exercised when Metherlin® Tablets are used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids.
ADVERSE REACTIONS
The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension and anaphylaxis has also been reported. Cerebrovascular accident, paraesthesia, ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block were also reported post-marketing.
Safety and effectiveness in pediatric patients have not been established.

DRUG DESCRIPTION
Metherlin (methylergonovine maleate) is a semi-synthetic ergot alkaloid used for the prevention and control of postpartum hemorrhage.

Active Ingredient: methylergonovine maleate, USP, 0.2 mg.

Inactive Ingredients: acacia, carnauba wax, D&C Red #7, FD&C Blue #1, gelatin special, lactose, maleic acid, mixed parabens, povidone, sodium benzoate, sodium hydroxide, starch, stearic acid, sucrose, talc, and titanium dioxide.

INDICATIONS
For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.

USES
This medication is used to help stop bleeding after delivery of the placenta in childbirth. Methylergonovine maleate belongs to a class of drugs known as ergot alkaloids. It works by increasing the stiffness of the uterus muscles after the last stage of labor. This effect decreases bleeding.

DOSAGE AND ADMINISTRATION
Intramuscularly
0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.
Intravenously
Dosage same as intramuscular.
Orally
One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

Metherlin® Tablets

SIDE EFFECTS
The most common adverse reaction is hypertension associated in several cases with seizure and/or headache. Hypotension has also been reported. Nausea and vomiting have occurred occasionally. Rarely observed reactions have included: acute myocardial infarction, transient chest pains, arterial spasm (coronary and peripheral), bradycardia, tachycardia, dyspnea, hematuria, thrombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitation, rash, and foul taste.1

There have been rare isolated reports of anaphylaxis, without a proven causal relationship to the drug product.
Drug Abuse And Dependence

Metherlin (methylergonovine maleate) has not been associated with drug abuse or dependence of either a physical or psychological nature.

WARNINGS
This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and cerebrovascular accidents. If I.V. administration is considered essential as a lifesaving measure, Metherlin (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.

PRECAUTIONS
Before taking methylergonovine maleate, tell your doctor or pharmacist if you are allergic to it; or to similar ergot alkaloids (e.g., ergonovine); or if you have any other allergies.
Metherlin-Injection

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: high blood pressure, a certain complication of pregnancy (toxemia).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: heart disease (e.g., venoatrial shunt, mitral valve stenosis), other complications during pregnancy (e.g., pre-eclampsia, eclampsia), a serious blood infection (sepsis), blood vessel problems (e.g., Raynaud's phenomenon, obliterative vascular disease), kidney problems, liver problems.

This drug may make you dizzy or drowsy. Use caution while driving, using machinery, or doing any activity that requires alertness. Limit or avoid alcoholic beverages.

STORAGE
Store at room temperature below 77 degrees F (25 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children

 



Note :
This product information is intended only for residents of the India. Taj Pharmaceuticals Limited,  medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world.

Information for Health Care Professionals

*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).

 

 






metherlin family

 

metherlin tablets
Larger View

 

metherlin tablets I.P.
Larger View

 

 

 

 

 

 

 

 

 

 

 

 

 

              
 Print page   Send by mail

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

   
   
PRODUCTS
 
 
   
   
   
  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market
    AFRICA
  ASIA PACIFIC
  EUROPE
  MIDDLE EAST
  THAILAND
  BANGLADESH
  NORTH AMERICA
  SOUTH AMERICA
  RUSSIA
  NEWZELAND
  UNITED KINGDOM
 

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 www.tajpharma.com

   

About Taj

Company

Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors

Countries

Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement